chapter  14
28 Pages

Outcomes and Cost Considerations with MRSA Infections /

Jack E. Brown, Jeremy Dengler, and Thomas P. Lodise, Jr.
ByJeremy Dengler and Thomas P. Lodise, Jr.

Over the past two decades, rates of antimicrobial resistance have

increased rapidly. Of the two million annual nosocomial infections in

the United States, more than 50% are caused by drug-resistant strains

of bacteria (1,2). Drug resistance has a considerable impact on patient

morbidity and mortality, and is a major economic burden for society with

yearly expenditures ranging from US$4 billion to US$30 billion (1-3).